PRLD compared with QTTB: revenue, margins and what each company keeps, and the suppliers and customers both name

PRLDPrelude Therapeutics Inc

Mkt capRevenueRevenue

QTTBQ32 Bio Inc.

Mkt capRevenueRevenue

Compare

PRLDPrelude Therapeutics Inc

QTTBQ32 Bio Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PRLD1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±17.9%▲+10.14%×0.56

QTTB2 of 4 reports

0 of 2at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±37.1%▲+2.40%×0.06

Q2 FY26±16.2%▲+2.07%×0.13

= impliedPRLD realized, solidQTTB realized, hatchedOne scale, both sides: full bar = 38%× = |realized| ÷ impliedSource: market data

PRLDPrelude Therapeutics Inc

3.57▼−12.38%· post 3.57

Mkt cap$325.6MRevenue$6MQ2 FY26

QTTBQ32 Bio Inc.

8.77▼−2.19%· post 8.77

ClosedNov 5 '26

Mkt cap$268.4MRevenue$54MQ4 FY25

Compare

ClosedNov 5 '26

PRLDPrelude Therapeutics Inc

QTTBQ32 Bio Inc.

3.57▼−12.38%post 3.57

Price

8.77▼−2.19%post 8.77

$325.6M

Mkt cap

$268.4M

Q2 FY26$6M

Revenue

$54MQ4 FY25

PRLD3.57▼−12.38%vsQTTB8.77▼−2.19%ClosedNov 5 '26